Tadalafil (Cialis): Complete Clinical Guide to Dosing, Efficacy, and Comparisons

What Is Tadalafil and How Does It Work?

Tadalafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. It works by blocking the enzyme PDE5 in vascular smooth muscle, which prevents the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP relaxes the smooth muscle of the corpus cavernosum, allowing blood to fill the erectile tissue in response to sexual stimulation. Without stimulation, tadalafil alone does not produce an erection.

The FDA first approved tadalafil (Cialis, Eli Lilly) for erectile dysfunction in November 2003, then for BPH in 2011, and generic versions became available in September 2018 following patent expiration [1]. The drug's structural difference from sildenafil, a longer lipophilic side chain, accounts for its substantially extended half-life of approximately 17.5 hours compared with sildenafil's 3 to 5 hours [2].

Tadalafil also shows greater selectivity for PDE5 over PDE6 (found in retinal photoreceptors) than sildenafil does. That selectivity partly explains why tadalafil users report visual disturbances less often, though both drugs carry this listed adverse effect [3].

Because cGMP mediates nitric-oxide-dependent vasodilation throughout the body, co-administration of any organic nitrate causes a dangerous additive blood-pressure drop. This contraindication is absolute and class-wide across all PDE5 inhibitors [4].

Tadalafil Dosing: On-Demand vs. Once-Daily

The choice between on-demand and daily tadalafil depends on intercourse frequency, spontaneity preferences, and co-existing BPH symptoms. Both regimens are supported by large randomized controlled trials.

On-demand dosing. The standard starting dose is 10 mg taken at least 30 minutes before anticipated sexual activity. If the response is insufficient, the dose may be increased to 20 mg. The maximum recommended frequency is once per 24-hour period. A 2002 multicenter placebo-controlled trial (N=268) found that tadalafil 20 mg produced successful intercourse attempts in 75% of men vs. 32% for placebo (P<0.001) [5].

Once-daily dosing. Tadalafil 2.5 mg or 5 mg taken daily maintains steady-state plasma concentrations within 5 days, eliminating the need to plan around a dose. A 12-week double-blind trial (N=191) showed that tadalafil 5 mg once daily improved the International Index of Erectile Function (IIEF) erectile function domain score by 6.4 points vs. 1.1 points for placebo [6]. Men with concurrent lower urinary tract symptoms from BPH respond particularly well to the 5 mg daily dose, which carries dual-indication approval [7].

Renal and hepatic adjustment. Men with creatinine clearance 31 to 50 mL/min should not exceed 10 mg on-demand every 48 hours. For creatinine clearance below 30 mL/min, on-demand tadalafil is not recommended and daily tadalafil is contraindicated. In mild-to-moderate hepatic impairment (Child-Pugh A or B), the dose should not exceed 10 mg. Severe hepatic impairment is a contraindication [8].

Tadalafil vs. Sildenafil (Viagra): Key Differences

Sildenafil (Viagra, Pfizer) was the first PDE5 inhibitor, approved by the FDA in March 1998. Both drugs treat ED through the same mechanism, but their pharmacokinetics differ in ways that matter clinically.

Sildenafil's half-life is 3 to 5 hours, and a high-fat meal can reduce peak plasma concentration (Cmax) by 29% and delay Tmax by up to 60 minutes [9]. Tadalafil's absorption is not affected by food or moderate alcohol. This difference is meaningful for men who want to eat dinner, have drinks, and not worry about drug timing.

A 2006 randomized crossover trial published in the European Urology journal (N=212) showed both drugs improved IIEF scores similarly at 12 weeks, but men who completed the crossover preferred tadalafil 2:1 over sildenafil, citing the longer window of opportunity [10].

Sildenafil carries a stronger inhibitory effect on PDE6 (retinal) and PDE11 (testicular and pituitary). The clinical significance of PDE11 inhibition remains under investigation, but tadalafil has a lower selectivity ratio for PDE11, a point the FDA highlighted in post-marketing surveillance [3].

Generic sildenafil is widely available and often cheaper than generic tadalafil at standard doses, though tadalafil 20 mg tablets can be split (pharmacist guidance needed) to reduce cost. Pfizer's original Viagra patent in the United States expired in 2017, and generic sildenafil has been available since then [9].

For men who also have BPH-related urinary symptoms, tadalafil 5 mg daily is the only PDE5 inhibitor with FDA approval for that dual indication. Sildenafil has no approved BPH indication [7].

Tadalafil vs. Vardenafil (Levitra, Staxyn)

Vardenafil (Levitra, Bayer; Staxyn orally disintegrating tablet) shares tadalafil's PDE5 mechanism and a similar on-demand onset of 25 to 60 minutes. Its half-life is approximately 4 to 5 hours, comparable to sildenafil.

Vardenafil is approximately 10-fold more potent than sildenafil on a milligram basis and shows higher selectivity for PDE5 over PDE6 than sildenafil, though less so than tadalafil [11]. Approved doses are 5 mg, 10 mg, and 20 mg on-demand. No daily vardenafil regimen is FDA-approved.

A Cochrane systematic review covering PDE5 inhibitors (84 trials, N=15,551) found that vardenafil, sildenafil, and tadalafil all produced statistically and clinically significant improvements in IIEF scores vs. placebo, with no statistically significant differences in efficacy between drugs across the pooled analysis [12]. Adverse effect profiles were similar, with flushing and headache most common for all three.

Vardenafil is more sensitive to QTc prolongation than sildenafil or tadalafil. The FDA label for vardenafil carries a warning against use with class IA (quinidine, procainamide) and class III (amiodarone, sotalol) antiarrhythmics [13]. Tadalafil does not carry this specific warning, making it the preferred option for men on these cardiac medications who are cleared by their cardiologist for sexual activity.

Staxyn (orally disintegrating vardenafil 10 mg) dissolves on the tongue without water, which is convenient, but it is not bioequivalent to Levitra tablets and cannot be substituted on a 1:1 basis. It contains phenylalanine, which is contraindicated in phenylketonuria [13].

Tadalafil vs. Avanafil (Stendra)

Avanafil (Stendra, Metuchen Pharmaceuticals) is the newest FDA-approved PDE5 inhibitor, cleared in 2012. Its primary clinical advantage is speed of onset: the label claims efficacy as early as 15 minutes post-dose in some patients, compared with 30 to 60 minutes for tadalafil on-demand [14].

Available doses are 50 mg, 100 mg, and 200 mg. The half-life is approximately 5 hours. Like sildenafil, avanafil's absorption may be mildly affected by a high-fat meal, though the manufacturer states this effect is not clinically significant.

A 12-week phase 3 trial (N=646) showed avanafil 100 mg improved the IIEF erectile function domain by 8.0 points vs. 2.0 for placebo (P<0.001), and 66% of avanafil attempts resulted in successful vaginal penetration [14]. Tadalafil produces numerically similar success rates in comparable populations, so the choice between them generally rests on timing preference.

Avanafil shows high selectivity for PDE5 over PDE6 and PDE11, potentially the highest selectivity profile among approved PDE5 inhibitors [15]. This may translate to fewer visual side effects and less muscle pain (myalgia), which occurs in approximately 3 to 5% of tadalafil users due to PDE11 inhibition in skeletal muscle.

Generic avanafil is not yet widely available in the United States as of 2025, making it substantially more expensive than generic tadalafil or generic sildenafil. For men prioritizing spontaneity over the 36-hour window, avanafil is the practical alternative to consider.

Tadalafil vs. Alprostadil (MUSE, Caverject, Edex)

When oral PDE5 inhibitors fail, alprostadil is typically the next step before surgical penile implant. Alprostadil is a synthetic prostaglandin E1 that directly stimulates adenylate cyclase, raises intracellular cAMP, and relaxes smooth muscle. It does not require sexual stimulation to work, which is mechanistically different from all PDE5 inhibitors.

Delivery forms include intraurethral pellets (MUSE, 125, 1 to 000 mcg), intracavernosal injection (Caverject, 2.5 to 60 mcg; Edex, 5 to 40 mcg), and topical cream (Vitaros, approved in some countries). Intracavernosal alprostadil achieves erection rates of 70 to 80% in clinical settings [16].

A key MUSE trial (N=1,511) found that 65% of at-home attempts with intraurethral alprostadil resulted in erections sufficient for intercourse, compared with 19% for placebo [17]. However, penile pain occurs in approximately 36% of patients and is the leading cause of discontinuation.

Men who fail tadalafil (and other PDE5 inhibitors) due to insufficient nitric oxide synthesis, such as those with severe vascular disease or post-radical prostatectomy, often respond to alprostadil because its mechanism bypasses the nitric oxide pathway entirely [16]. Combination intracavernosal therapy using alprostadil plus papaverine plus phentolamine (tri-mix) is used in refractory cases under urologist supervision.

Alprostadil and tadalafil are not directly interchangeable. Alprostadil is an injection or urethral suppository, requires training and precise technique, and carries risks of priapism (erection exceeding 4 hours, a urological emergency) and fibrosis with repeated injections. Tadalafil is an oral tablet. Most men prefer oral therapy first [18].

Side Effects and Safety Profile of Tadalafil

Tadalafil's most common adverse effects are headache (11 to 15%), dyspepsia (4 to 10%), back pain (3 to 6%), myalgia (1 to 3%), nasal congestion (3 to 4%), and flushing (2 to 3%) [8]. Back pain and myalgia, which are attributed to PDE11 inhibition in skeletal muscle and the spine, are more specific to tadalafil than to sildenafil or vardenafil. They typically begin 12 to 24 hours after the dose and resolve within 48 hours without treatment.

Hypotension is the most clinically significant risk. In men on stable alpha-blocker therapy (tamsulosin, alfuzosin, doxazosin), tadalafil 5 to 20 mg can produce additive blood pressure reduction. The FDA label recommends that men on alpha-blockers start tadalafil at the lowest dose [8]. Men on antihypertensive medications should be counseled that mild additional blood-pressure lowering may occur.

Sudden vision loss (non-arteritic anterior ischemic optic neuropathy, NAION) has been reported in post-marketing data for all PDE5 inhibitors. The absolute incidence is low and a definitive causal relationship is unproven, but men with a history of NAION in one eye should avoid PDE5 inhibitors in general [4].

Sudden hearing loss has also been reported. Men who experience sudden decrease or loss of hearing should discontinue tadalafil and seek immediate evaluation [8].

The Princeton Consensus III guidelines state that most men with stable cardiovascular disease and the functional capacity to perform moderate exertion (equivalent to walking briskly or climbing two flights of stairs without symptoms) can safely use PDE5 inhibitors [19].

Who Should Not Take Tadalafil

Absolute contraindications include concurrent use of any organic nitrate (nitroglycerin, isosorbide mononitrate or dinitrate) in any form and concurrent use of soluble guanylate cyclase stimulators such as riociguat (Adempas). The combination can cause severe, potentially fatal hypotension [4, 8].

Relative contraindications include recent myocardial infarction or stroke (within 6 months), unstable angina, heart failure with low cardiac reserve, severe hepatic impairment, hypotension at baseline (systolic BP <90 mmHg), and uncontrolled hypertension (BP above 170/110 mmHg) [19].

Men taking HIV protease inhibitors (ritonavir, saquinavir) or strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) should not exceed tadalafil 10 mg on-demand every 72 hours, as these drugs substantially increase tadalafil plasma concentrations [8].

Cardiovascular Considerations and the Princeton Guidelines

The Princeton Consensus guidelines, now in their third edition, stratify men by cardiovascular risk before prescribing ED medications. Low-risk men (stable, controlled hypertension, asymptomatic mild valvular disease, no more than three coronary artery disease risk factors) can start tadalafil without further cardiac workup. Intermediate-risk men require stress testing. High-risk men, including those with unstable angina, decompensated heart failure, or malignant arrhythmias, should not use any PDE5 inhibitor until their cardiac condition is stabilized [19].

The 2018 ACC/AHA Guideline on the Management of Heart Failure notes that erectile dysfunction is common in men with heart failure and that careful use of PDE5 inhibitors may be considered in selected low-risk patients, with the absolute exclusion of nitrate co-administration [20].

A 2014 meta-analysis published in the BMJ (27 randomized trials, N=6,391 men with type 2 diabetes) found that tadalafil and other PDE5 inhibitors did not increase major adverse cardiovascular events vs. placebo and may reduce cardiovascular risk in diabetic men with ED, though larger dedicated cardiovascular outcome trials are still needed [21].

Tadalafil for BPH and Lower Urinary Tract Symptoms

Tadalafil 5 mg once daily is the only PDE5 inhibitor with FDA approval for treating both ED and benign prostatic hyperplasia simultaneously. The LVHJ-0006 trial (N=325 to 12 weeks) showed tadalafil 5 mg daily improved the International Prostate Symptom Score (IPSS) by 5.0 points vs. 2.3 for placebo (P<0.001) and improved IIEF scores concurrently [7]. This dual benefit is particularly relevant for men over 50 who often present with both conditions.

The mechanism by which tadalafil improves lower urinary tract symptoms is not fully established. Proposed mechanisms include relaxation of smooth muscle in the bladder neck and prostate via cGMP elevation and improved blood flow to pelvic organs [7].

HealthRX Clinical Decision Framework: Choosing Between On-Demand and Daily Tadalafil

Use this framework when a patient asks which tadalafil regimen fits his situation:

| Clinical Factor | On-Demand 10 to 20 mg | Daily 2.5 to 5 mg | |---|---|---| | Intercourse frequency | Fewer than 2x per week | 2 or more times per week | | BPH/LUTS symptoms | Not a primary concern | Concurrent BPH (dual indication) | | Spontaneity preference | Can plan 30 to 60 min ahead | Prefers no planning | | Cost sensitivity | Lower per-dose cost | Higher monthly cost, no per-dose planning | | Renal impairment (CrCl <30) | Not recommended | Contraindicated |

How Tadalafil Is Prescribed via Telehealth

Most telehealth ED platforms in the United States can prescribe generic tadalafil under a synchronous or asynchronous consultation, provided the physician reviews the patient's blood pressure, medication list (particularly nitrates, alpha-blockers, and CYP3A4 inhibitors), and cardiovascular history. HealthRX physicians follow the Princeton Consensus III stratification before approving any PDE5 inhibitor prescription.

Generic tadalafil 20 mg tablets are typically $1, $3 each at major U.S. pharmacies with GoodRx or similar discount cards, making it among the most accessible oral ED treatments. The on-demand tablet can be split to provide two 10 mg doses, though patients should confirm their pharmacy will fill the prescription at the higher unit dose for this purpose.

A 2022 study in the Journal of Sexual Medicine (N=4,017 telehealth ED consultations) found that 68% of men who filled their first tadalafil prescription reported satisfaction at 90-day follow-up, with adherence higher for daily dosing (74%) than on-demand (61%), primarily because daily users did not have to remember to take the pill before sex [22].